Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Mar 17, 2017 2:50pm

165 Views

Post# 25994996

RE:RE:RE:RE:RE:REPATHA

Well this is interesting. The ~20% RRR in 3-point MACE for Repatha in FOURIER was due to a 27% reduction in heart attacks and a 21% reduction in strokes, but "Consistent with recent trials of more intensive LDL lowering, there was no observed effect on cardiovascular mortality." However, in the EMPA-REG OUTCOME trial with Jardiance in diabetics, the ~14% RRR in 3-point MACE was due to 38% reduction in cardiovascular death with no significant effect on heart attack or stroke.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity